Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children: a Prospective, Randomized Crossover Trial

NCT06890143 is registered in ClinicalTrials.gov with Children's Hospital of Fudan University as lead sponsor.

NCT NCT06890143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06890143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children: a Prospective, Randomized Crossover Trial
Lead sponsor
Children's Hospital of Fudan University
Phase
Phase 3
Overall status
Recruiting
Start date
March 22, 2025
Completion date
March 31, 2027
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric hereditary kidney diseases